Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
10.83
-0.33 (-2.96%)
Jun 5, 2025, 10:25 AM - Market open
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
Country | United States |
Founded | 2018 |
IPO Date | Sep 13, 2024 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 55 |
CEO | Claire Mazumdar Clemon |
Contact Details
Address: 116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States | |
Phone | 617 468 4219 |
Website | bicara.com |
Stock Details
Ticker Symbol | BCAX |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0002023658 |
CUSIP Number | 055477103 |
ISIN Number | US0554771032 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Claire Mazumdar Clemon M.B.A., Ph.D. | Chief Executive Officer and Director |
Ryan Cohlhepp Pharm.D. | President, Chief Operating Officer and Director |
Ivan Hyep M.B.A. | Chief Financial Officer |
Lara S. Meisner J.D. | Chief Legal Officer and Corporate Secretary |
Rachel Salazar | SVice President of Research & Development Strategy and Operations |
Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations and Supply Chain |
Dr. David Raben M.D. | Chief Medical Officer |
Angela Windt | Vice President and Head of Regulatory Affairs |
Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical and Medical Affairs |
Jean-Paul Rodrique | Senior Vice President and Global Head of Quality Assurance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2025 | SCHEDULE 13G | Filing |
May 13, 2025 | 10-Q | Quarterly Report |
May 13, 2025 | 8-K | Current Report |
May 12, 2025 | SCHEDULE 13G/A | Filing |
Apr 25, 2025 | ARS | Filing |
Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
Mar 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 27, 2025 | 10-K | Annual Report |
Mar 27, 2025 | 8-K | Current Report |